Literature DB >> 23138387

Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time.

Aymeric Guibal1, Caroline Bertin, Sophie Egels, Eric Savier, Philippe A Grenier, Olivier Lucidarme.   

Abstract

OBJECTIVES: To describe the early patterns of liver lesions successfully treated with radiofrequency ablation (RFA) or cryoablation (CA) and their changes over time.
METHODS: Twenty-two RFA-treated and 17 CA-treated patients underwent CEUS from week 1 to year 3 post-ablation. Patterns, margins and volumes of RF-induced and cryolesions were evaluated and compared over time.
RESULTS: After contrast enhancement, shortly after ablation, undefined margins with persistent enhancing small vessels penetrating >2 mm into the treated zone were significantly more frequent after CA (67 %) than RFA (22 %) (P < 0.02). During the arterial phase, a thin, enhancing marginal rim was seen during week 1 (T1) in around 28 % of RF lesions, while 75 % of cryolesions had thick enhancing rims (P < 0.02). The mean RF-induced lesion volume, maximum at T1 (44.1 ± 37.5 ml), shrank slowly over time, remaining clearly visible at 1 year (8.3 ± 7.4 ml). Cryolesions shrank faster (P = 0.009), from an average of 16.6 ± 7.1 ml at T1 to 1.7 ± 1.3 ml 1-year post-ablation.
CONCLUSION: RF-induced and cryolesions differ, particularly their margins and shrinkage rates. Knowing these differences allows avoidance of incomplete treatment or falsely diagnosed recurrence, especially after CA. KEY POINTS: • Contrast-enhanced ultrasound (CEUS) provides new follow-up information following hepatic radiological inyervention. • CEUS provides good visualisation of vascular modifications after thermoablation. • RFA-induced lesions and cryoablated lesions differ. • Knowledge about RF and cryolesion patterns is essential for correct CEUS follow-up. • Cryolesions have thicker peripheral inflammatory reactions and shrink faster than RFA-induced lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138387     DOI: 10.1007/s00330-012-2702-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

Review 1.  Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance.

Authors:  S N Goldberg; G S Gazelle; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  2000-02       Impact factor: 3.959

2.  Nephrectomy after radiofrequency ablation-induced ureteropelvic junction obstruction: potential complication and long-term assessment of ablation adequacy.

Authors:  D Brooke Johnson; M Hossein Saboorian; David A Duchene; Kenneth Ogan; Jeffrey A Cadeddu
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

3.  Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience.

Authors:  A R Zlotta; T Wildschutz; G Raviv; M O Peny; D van Gansbeke; J C Noel; C C Schulman
Journal:  J Endourol       Date:  1997-08       Impact factor: 2.942

4.  Freezing injury to large blood vessels in dogs. With comments on the effect of experimental freezing of bile ducts.

Authors:  A A Gage; G Fazekas; E E Riley
Journal:  Surgery       Date:  1967-05       Impact factor: 3.982

5.  Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma?

Authors:  P Ricci; V Cantisani; F Drudi; E Pagliara; M Bezzi; F Meloni; F Calliada; S M Erturk; V D'Andrea; U D'Ambrosio; R Passariello
Journal:  Ultraschall Med       Date:  2009-03-11       Impact factor: 6.548

6.  Clinical experience with open renal cryoablation.

Authors:  D B Rukstalis; M Khorsandi; F U Garcia; D M Hoenig; J K Cohen
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

7.  The radiographic evolution of radio frequency ablated renal tumors.

Authors:  Edward D Matsumoto; Lori Watumull; D Brooke Johnson; Kenneth Ogan; Grant D Taylor; Shellie Josephs; Jeffrey A Cadeddu
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

Review 8.  Imaging appearances following thermal ablation.

Authors:  S Smith; A Gillams
Journal:  Clin Radiol       Date:  2007-10-01       Impact factor: 2.350

9.  Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors.

Authors:  Sid Kerkar; Arthur M Carlin; Richard L Sohn; Christopher Steffes; James Tyburski; Peter Littrup; Donald Weaver
Journal:  Surgery       Date:  2004-10       Impact factor: 3.982

10.  Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process.

Authors:  Min-Hua Chen; Wei Yang; Kun Yan; Ming-Wu Zou; Luigi Solbiati; Ji-Bin Liu; Ying Dai
Journal:  Radiology       Date:  2004-05-27       Impact factor: 11.105

View more
  10 in total

1.  Comparative study of conventional US, contrast enhanced US and enhanced MR for the follow-up of prostatic radiofrequency ablation.

Authors:  Chao Feng; Bin Hu; Bing Hu; Lei Chen; Jia Li; Jin Huang
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

2.  Assessment of liver ablation using cone beam computed tomography.

Authors:  Mohamed Abdel-Rehim; Maxime Ronot; Annie Sibert; Valérie Vilgrain
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

3.  Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Yuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Takayuki Iwamoto; Junya Okabe; Manabu Takamura; Norihiko Fujita; Masatoshi Hori; Tetsuo Takehara; Masatoshi Kudo; Takamichi Murakami
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

Review 4.  Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment.

Authors:  Davide Roccarina; Matteo Garcovich; Maria Elena Ainora; Laura Riccardi; Maurizio Pompili; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  World J Hepatol       Date:  2015-07-18

Review 5.  Role of interventional radiology in managing pediatric liver tumors : Part 2: percutaneous interventions.

Authors:  C Matthew Hawkins; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh S Thakor; Richard B Towbin; Anne Marie Cahill; Matthew P Lungren
Journal:  Pediatr Radiol       Date:  2018-02-02

6.  Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.

Authors:  Yu Wang; Al Christopher De Leon; Reshani Perera; Eric Abenojar; Ramamurthy Gopalakrishnan; James P Basilion; Xinning Wang; Agata A Exner
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

7.  Contrast-enhanced ultrasound for evaluation of high-intensity focused ultrasound treatment of benign uterine diseases: retrospective analysis of contrast safety.

Authors:  Chong-Qing Cheng; Rui-Tao Zhang; Yu Xiong; Li Chen; Jian Wang; Guo-Hua Huang; Ke-Quan Li; Lian Zhang; Jin Bai
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

Review 8.  Contrast-enhanced ultrasonography of the liver using SonoVue.

Authors:  Giovanna Ferraioli; Maria Franca Meloni
Journal:  Ultrasonography       Date:  2017-07-12

9.  Irreversible electroporation in patients with liver tumours: treated-area patterns with contrast-enhanced ultrasound.

Authors:  Linyu Zhou; Shanyu Yin; Weilu Chai; Qiyu Zhao; Guo Tian; Danxia Xu; Tian'an Jiang
Journal:  World J Surg Oncol       Date:  2020-11-23       Impact factor: 2.754

Review 10.  Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines.

Authors:  Liliana Chiorean; Claudio Tana; Barbara Braden; Cosmin Caraiani; Zeno Sparchez; Xin-Wu Cui; Ulrich Baum; Christoph F Dietrich
Journal:  Med Princ Pract       Date:  2016-06-17       Impact factor: 1.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.